MedTrace Logo

Clinical Trial of the Use of Ketamine in Treatment Resistant Depression

NCT02610712 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-09-21

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission and inflammatory serum markers.

Conditions

  • Depressive Disorder, Treatment-Resistant

Interventions

DRUG

Ketamine

Sponsors & Collaborators

  • National Institute of Neurology and Neurosurgery, Mexico

    lead OTHER

Principal Investigators

  • Rodrigo Pérez-Esparza, MD · National Institute of Neurology and Neurosurgery, Mexico

  • Jesús Ramírez-Bermúdez, MD, MSc · National Institute of Neurology and Neurosurgery, Mexico

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02610712 on ClinicalTrials.gov